Pelthos Therapeutics
PTHS
4 hedge funds and large institutions have $16K invested in Pelthos Therapeutics in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.1% less ownership
Funds ownership: 0.15% → 0.04% (-0.1%)
20% less funds holding
Funds holding: 5 → 4 (-1)
73% less capital invested
Capital invested by funds: $59.6K → $16K (-$43.6K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
-$33.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$7.61K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
1
Two Sigma Securities
New York
| $9.2K | -$7.61K | -1,171 | -45% |
|
2
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
| $6.67K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $162 | -$7 | -1 | -4% |
|
4
Bank of America
Charlotte,
North Carolina
| $8 | – | – | – |
|
|
APP
5
Avantax Planning Partners
Dubuque,
Iowa
| – | -$33.5K | -4,721 | Closed |
|
PTHS Hedge Fund Activity: Q4 2024 in Review
4 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q4 2024, worth a combined $16K — down 73% from $59.6K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PTHS and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was Avantax Planning Partners, exiting entirely with an estimated $33.5K sold.
- 4 institutional investors held Pelthos Therapeutics (PTHS) as of Q4 2024, down from 5 in Q3 2024.
- Funds reported $16K of Pelthos Therapeutics stock for Q4 2024, down 73% quarter-over-quarter.
- 0 funds opened new Pelthos Therapeutics positions in Q4 2024 and 1 closed out, a net change of -1 holder.
- The largest Pelthos Therapeutics seller in Q4 2024 was Avantax Planning Partners, an estimated $33.5K sold.
Based on aggregated 13F filings for Q4 2024.